20/20 BioLabs Secures Exclusive U.S. License for ROKIT Healthcare’s CKD Prediction Tech

Key Facts

120/20 BioLabs (Nasdaq: AIDX) entered into an exclusive U.S. technology license agreement with ROKIT Healthcare Inc.

2The company will integrate advanced Chronic Kidney Disease (CKD) prediction technology into its OneTest for Longevity program.

3The technology uses inflammatory biomarker tracking to enhance responses to 3-D bio-printed therapies.

20/20 BioLabs (Nasdaq: AIDX) has announced an exclusive U.S. technology license agreement with ROKIT Healthcare Inc. to advance its diagnostic capabilities. Under the deal, the company will integrate sophisticated Chronic Kidney Disease (CKD) prediction technology into its flagship OneTest for Longevity program. This technology utilizes inflammatory biomarker tracking to optimize patient responses to 3D bio-printed therapies. By leveraging AI-powered blood tests, the partnership aims to improve the early detection of chronic diseases and enhance regenerative health outcomes. This strategic move expands AIDX's product portfolio within the high-growth longevity market. Investors view this expansion into advanced diagnostics as a positive development for the biotech firm's market positioning and long-term growth potential.

Open on chart